Sisti Andrea, Sisti Giovanni, Oranges Carlo Maria
General and Specialist Surgery Department, Plastic Surgery Division, University of Siena, Siena, Italy.
Dermatol Online J. 2015 Feb 15;21(2):13030/qt8rj4k7r6.
At present, case studies are the only source of results on imiquimod (IMQ) as monotherapy in cutaneous metastases from melanoma. We analyzed these studies in the literature with the aim to review the efficacy of IMQ as topical treatment for melanoma skin metastases.
The aim of our review was to critically assess the studies evaluating the monotherapy with IMQ cream in the treatment of cutaneous metastases from melanoma.
A PubMed search was conducted using the term "melanoma" combined with "metastases" and "imiquimod".
57 studies were identified. 46 did not meet inclusion criteria, leaving 11 case studies. Overall, 17 patients were treated in these 11 studies. Main treatment choice was 5% IMQ cream applied once daily (for 6-8 hours), five days per week under occlusive conditions, in 8/17 patients (47,1%). IMQ was applied 3 times weekly in 4/17 patients (23,53%), daily in 2/17 patients (11,76%) and twice daily in 2/17 patients (11,76%). Treatment length was variable, with a mean duration of 22 weeks (range from 8 weeks to 72 weeks). The majority of studies showed that IMQ is an effective and safe treatment for metastases of melanoma. Even if this treatment doesn't stop the disease progression, it is mainly useful in clearing cutaneous metastases spreading from melanoma primary tumor.
目前，病例研究是关于咪喹莫特（IMQ）作为黑色素瘤皮肤转移瘤单一疗法结果的唯一来源。我们分析了文献中的这些研究，旨在综述IMQ作为黑色素瘤皮肤转移瘤局部治疗的疗效。
我们综述的目的是严格评估评估IMQ乳膏单一疗法治疗黑色素瘤皮肤转移瘤的研究。
使用“黑色素瘤”与“转移瘤”和“咪喹莫特”相结合的术语在PubMed上进行检索。
共识别出57项研究。46项不符合纳入标准，剩下11项病例研究。总体而言，这11项研究共治疗了17例患者。主要治疗方案是8/17例患者（47.1%）在封闭条件下，每周五天，每天一次（持续6 - 8小时）涂抹5%的IMQ乳膏。4/17例患者（23.53%）每周应用IMQ三次，2/17例患者（11.76%）每天应用，2/17例患者（11.76%）每天应用两次。治疗时长各不相同，平均持续时间为22周（范围从8周到72周）。大多数研究表明，IMQ是治疗黑色素瘤转移瘤的一种有效且安全的疗法。即使这种治疗不能阻止疾病进展，但它主要有助于清除黑色素瘤原发肿瘤扩散而来的皮肤转移瘤。
